<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="685">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863602</url>
  </required_header>
  <id_info>
    <org_study_id>112728</org_study_id>
    <nct_id>NCT01863602</nct_id>
  </id_info>
  <brief_title>Special Drug Use Investigation for LAMICTALÂ® (Long Term)</brief_title>
  <official_title>Special Drug Use Investigation for LAMICTAL (Long Term)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this post-marketing surveillance (PMS) are to grasp the actual use of
      lamotrigine tablets to collect safety information in the long-term use according to seizure
      type and concomitant antiepileptic drug (AED), and to confirm its efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The incidence of adverse drug reactions</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of skin disorder after the start of treatment</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Presence or absence of skin disorder and its details after the start of treatment will be investigated as a priority investigation item</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall improvement of subjects' symptoms</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigators will assess the overall improvement as &quot;remarkably improved&quot;. &quot;improved&quot;, &quot;slightly improved&quot;, &quot;unchanged&quot; or &quot;worsened&quot; on the basis of the degree of change in frequency of seizures, strength, span and other related symptoms.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Subjects prescribed lamotrigine tablets</arm_group_label>
    <description>Subjects with epilepsy with partial seizures, tonic-clonic seizuresm or generalized seizures of Lennox-Gastaut syndrome to whom lamotrigine tablets are administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine tablets</intervention_name>
    <description>Administered for long-term according to the prescribing information in the locally approved label by the authorities.</description>
    <arm_group_label>Subjects prescribed lamotrigine tablets</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult (&gt;=15 to &lt;65 years) and pediatric (&gt;=2 to &lt;15 years) subjects with epilepsy with the
        following seizure type who use lamotrigine tablets

          -  Partial seizures

          -  Tonic-clonic seizures

          -  Generalized seizures of Lennox-Gastaut syndrome
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with epilepsy with partial seizures, tonic-clonic seizuresm or generalized
             seizures of Lennox-Gastaut syndrome

          -  Subjects who are treated with lamotrigine tablets

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 10, 2015</lastchanged_date>
  <firstreceived_date>October 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lamotrigine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
